170 related articles for article (PubMed ID: 21319260)
1. Alternative lengthening of telomeres--an enhanced chromosomal instability in aggressive non-MYCN amplified and telomere elongated neuroblastomas.
Lundberg G; Sehic D; Länsberg JK; Øra I; Frigyesi A; Castel V; Navarro S; Piqueras M; Martinsson T; Noguera R; Gisselsson D
Genes Chromosomes Cancer; 2011 Apr; 50(4):250-62. PubMed ID: 21319260
[TBL] [Abstract][Full Text] [Related]
2. Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations.
Farooqi AS; Dagg RA; Choi LM; Shay JW; Reynolds CP; Lau LM
J Neurooncol; 2014 Aug; 119(1):17-26. PubMed ID: 24792489
[TBL] [Abstract][Full Text] [Related]
3. Telomerase activation by genomic rearrangements in high-risk neuroblastoma.
Peifer M; Hertwig F; Roels F; Dreidax D; Gartlgruber M; Menon R; Krämer A; Roncaioli JL; Sand F; Heuckmann JM; Ikram F; Schmidt R; Ackermann S; Engesser A; Kahlert Y; Vogel W; Altmüller J; Nürnberg P; Thierry-Mieg J; Thierry-Mieg D; Mariappan A; Heynck S; Mariotti E; Henrich KO; Gloeckner C; Bosco G; Leuschner I; Schweiger MR; Savelyeva L; Watkins SC; Shao C; Bell E; Höfer T; Achter V; Lang U; Theissen J; Volland R; Saadati M; Eggert A; de Wilde B; Berthold F; Peng Z; Zhao C; Shi L; Ortmann M; Büttner R; Perner S; Hero B; Schramm A; Schulte JH; Herrmann C; O'Sullivan RJ; Westermann F; Thomas RK; Fischer M
Nature; 2015 Oct; 526(7575):700-4. PubMed ID: 26466568
[TBL] [Abstract][Full Text] [Related]
4. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
[TBL] [Abstract][Full Text] [Related]
5. In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression.
Ribatti D; Raffaghello L; Pastorino F; Nico B; Brignole C; Vacca A; Ponzoni M
Int J Cancer; 2002 Dec; 102(4):351-4. PubMed ID: 12402304
[TBL] [Abstract][Full Text] [Related]
6. Correlation of MYCN amplification with MCM7 protein expression in neuroblastomas: a chromogenic in situ hybridization study in paraffin sections.
Tsai HY; Hsi BL; Hung IJ; Yang CP; Lin JN; Chen JC; Tsai SF; Huang SF
Hum Pathol; 2004 Nov; 35(11):1397-403. PubMed ID: 15668898
[TBL] [Abstract][Full Text] [Related]
7. The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma.
Bogen D; Brunner C; Walder D; Ziegler A; Abbasi R; Ladenstein RL; Noguera R; Martinsson T; Amann G; Schilling FH; Ussowicz M; Benesch M; Ambros PF; Ambros IM
Int J Cancer; 2016 Jul; 139(1):153-63. PubMed ID: 26910568
[TBL] [Abstract][Full Text] [Related]
8. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
Spitz R; Hero B; Ernestus K; Berthold F
Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
[TBL] [Abstract][Full Text] [Related]
9. Telomere biology including TERT rearrangements in neuroblastoma: a useful indicator for surgical treatments.
Kawashima M; Kojima M; Ueda Y; Kurihara S; Hiyama E
J Pediatr Surg; 2016 Dec; 51(12):2080-2085. PubMed ID: 27793328
[TBL] [Abstract][Full Text] [Related]
10. A MYCN-amplified cell line derived from a long-term event-free survivor among our sixteen established neuroblastoma cell lines.
Sugimoto T; Gotoh T; Yagyu S; Kuroda H; Iehara T; Hosoi H; Ohta S; Ohira M; Nakagawara A
Cancer Lett; 2013 Apr; 331(1):115-21. PubMed ID: 23268333
[TBL] [Abstract][Full Text] [Related]
11. The coamplification pattern of the MYCN amplicon is an invariable attribute of most MYCN-amplified human neuroblastomas.
Weber A; Starke S; Bergmann E; Christiansen H
Clin Cancer Res; 2006 Dec; 12(24):7316-21. PubMed ID: 17189403
[TBL] [Abstract][Full Text] [Related]
12. Telomerase-independent telomere length maintenance in the absence of alternative lengthening of telomeres-associated promyelocytic leukemia bodies.
Fasching CL; Bower K; Reddel RR
Cancer Res; 2005 Apr; 65(7):2722-9. PubMed ID: 15805271
[TBL] [Abstract][Full Text] [Related]
13. Chromosome imbalances and alterations of AURKA and MYCN genes in children with neuroblastoma.
Inandiklioğlu N; Yilmaz S; Demirhan O; Erdoğan S; Tanyeli A
Asian Pac J Cancer Prev; 2012; 13(11):5391-7. PubMed ID: 23317189
[TBL] [Abstract][Full Text] [Related]
14. Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors.
Berbegall AP; Villamón E; Piqueras M; Tadeo I; Djos A; Ambros PF; Martinsson T; Ambros IM; Cañete A; Castel V; Navarro S; Noguera R
Oncogene; 2016 Mar; 35(11):1423-32. PubMed ID: 26119945
[TBL] [Abstract][Full Text] [Related]
15. Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology.
Nakagawa A; Matsuoka K; Okita H; Iwafuchi H; Hori H; Kumagai M
Pediatr Dev Pathol; 2011; 14(2):87-92. PubMed ID: 21288077
[TBL] [Abstract][Full Text] [Related]
16. Telomere maintenance in Wilms tumors: first evidence for the presence of alternative lengthening of telomeres mechanism.
Venturini L; Daidone MG; Motta R; Collini P; Spreafico F; Terenziani M; Piva L; Radice P; Perotti D; Zaffaroni N
Genes Chromosomes Cancer; 2011 Oct; 50(10):823-9. PubMed ID: 21769957
[TBL] [Abstract][Full Text] [Related]
17. A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas.
Henson JD; Hannay JA; McCarthy SW; Royds JA; Yeager TR; Robinson RA; Wharton SB; Jellinek DA; Arbuckle SM; Yoo J; Robinson BG; Learoyd DL; Stalley PD; Bonar SF; Yu D; Pollock RE; Reddel RR
Clin Cancer Res; 2005 Jan; 11(1):217-25. PubMed ID: 15671549
[TBL] [Abstract][Full Text] [Related]
18. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
[TBL] [Abstract][Full Text] [Related]
19. How Do Telomere Abnormalities Regulate the Biology of Neuroblastoma?
Akter J; Kamijo T
Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439779
[TBL] [Abstract][Full Text] [Related]
20. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index.
Kobayashi C; Monforte-Munoz HL; Gerbing RB; Stram DO; Matthay KK; Lukens JN; Seeger RC; Shimada H
Cancer; 2005 Jan; 103(1):174-80. PubMed ID: 15549714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]